All In Biotech

Drug Trial Radar · NCT05117632

ALTO-100 in MDD and/or PTSD

An Open-label Study of ALTO-100 in Adults With Major Depressive Disorder and/or Post-traumatic Stress Disorder

Last checked: Nov 20, 2026Latest source record: Dec 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

245

Actual

Start

Dec 20, 2021

Primary completion

Dec 1, 2022

Study completion Dec 9, 2022

Sponsor

Lead sponsor
Alto NeuroscienceIndustry
Sponsor type
Industry
First posted
Nov 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.

Conditions

  • Major Depressive Disorder
  • Post Traumatic Stress Disorder

Interventions

  • ALTO-100 PO tabletDrug

    one tablet twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Montgomery-Åsberg Depression Rating Scale (MADRS)Time frame: Measured 5 times over 8 weeks
  2. To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Clinical Global Impression scale - Severity (CGI-S)Time frame: Measured 5 times over 8 weeks
  3. To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)Time frame: Measured 3 times over 8 weeks
  4. Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-100Time frame: From the signing of the ICF until the follow-up visit (up to 12 weeks)
  5. Number of Participants With Clinically Significant Vital Signs Abnormalities as a Measure of Safety and Tolerability of ALTO-100Time frame: From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)
  6. Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-100Time frame: From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Site 136

    Tempe, Arizona

  • Site 139

    Little Rock, Arkansas

  • Site 141

    Costa Mesa, California

  • Site 118

    Fresno, California

  • Site 116

    Martinez, California

  • Site 116

    Mather, California

  • Site 150

    Boca Raton, Florida

  • Site 112

    Doral, Florida

  • Site 155

    Elgin, Illinois

  • Site 137

    Noblesville, Indiana

  • Site 151

    Baltimore, Maryland

  • Site 109

    Belmont, Massachusetts

  • Site 108

    Jackson, Mississippi

  • Site 142

    Lincoln, Nebraska

  • Site 144

    Las Vegas, Nevada

  • Site 146

    Middleburg Heights, Ohio

  • Site 147

    Fort Worth, Texas

  • Site 148

    Fort Worth, Texas

  • Site 120

    Houston, Texas

  • Site 113

    Houston, Texas

  • Site 121

    Draper, Utah

  • Site 105

    Seattle, Washington

  • NTC Seattle (105a)

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.